New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants

As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are cri...

Full description

Saved in:
Bibliographic Details
Published in:BMC medicine Vol. 21; no. 1; pp. 177 - 3
Main Authors: Srikantiah, Padmini, Klugman, Keith P.
Format: Journal Article
Language:English
Published: London BioMed Central 15.05.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Age
Babies
Biomedicine
Burden
Care and treatment
Control
Cost analysis
Cost effectiveness
Cost of Illness
Cost-Benefit Analysis
Data analysis
Developing Countries
Disease prevention
Dosage and administration
Editorial
Health care expenditures
Hospitalization
Households
Humans
Identification and classification
Illnesses
Immunization
Income
Infant
Infant monoclonal antibody
Infants (Newborn)
Low- and middle-income countries
Maternal vaccine
Medicine
Medicine & Public Health
Monoclonal antibodies
Mortality
Pediatrics
Pneumonia
Public health
Respiratory diseases
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
Respiratory tract
Respiratory tract diseases
Strengthening the evidence base to evaluate preventive interventions against respiratory syncytial virus (RSV)
Surveillance
Vaccines
South Africa
Kenya
Maternal vaccine
Infant monoclonal antibody
Respiratory syncytial virus
Burden
Cost effectiveness
Low- and middle-income countries
ISSN:1741-7015, 1741-7015
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As new, efficacious respiratory syncytial virus (RSV) immunization products reach the market, affordable pricing as well as improved estimation of disease burden and the full potential and cost effectiveness of RSV prevention in the hardest hit geographies in low- and middle-income countries are critical to inform country adoption and enable maximum impact against infant disease and mortality globally. The data reported in the special issue underscore the enormous burden, and associated cost, of RSV disease in young infants in several LMICs, including Kenya and South Africa, as well as the potential for RSV maternal vaccines or long-acting monoclonal antibodies, to be cost-effective and possibly even cost-saving.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ObjectType-Article-3
ISSN:1741-7015
1741-7015
DOI:10.1186/s12916-023-02883-x